479 related articles for article (PubMed ID: 18382877)
21. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
Sornsukolrat S; Tuipae S
J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
[TBL] [Abstract][Full Text] [Related]
23. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
25. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy.
Ødegaard E; Staff AC; Langebrekke A; Engh V; Onsrud M
Acta Obstet Gynecol Scand; 2007; 86(5):620-6. PubMed ID: 17464594
[TBL] [Abstract][Full Text] [Related]
26. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
27. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.
Fauvet R; Demblocque E; Morice P; Querleu D; Daraï E
Ann Surg Oncol; 2012 Mar; 19(3):941-7. PubMed ID: 21879267
[TBL] [Abstract][Full Text] [Related]
28. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
29. [Effect of retroperitoneal lymphadenectomy on survival of patients with epithelial ovarian cancer].
Xiong ZF; Wang ZH; Wang SX
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):77-80. PubMed ID: 12783692
[TBL] [Abstract][Full Text] [Related]
30. [Serous micropapillary invasive carcinoma. Case report on both ovaries].
Espinosa de los Monteros Franco VA; Padilla Rodríguez AL
Ginecol Obstet Mex; 2007 Nov; 75(11):682-6. PubMed ID: 18697443
[TBL] [Abstract][Full Text] [Related]
31. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
32. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
33. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
34. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland.
Kumpulainen S; Kuoppala T; Leminen A; Komulainen M; Puistola U; Sankila R; Mäkinen J; Grénman S
Acta Obstet Gynecol Scand; 2007; 86(5):610-4. PubMed ID: 17464592
[TBL] [Abstract][Full Text] [Related]
35. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
Chan JK; Zhang M; Kaleb V; Loizzi V; Benjamin J; Vasilev S; Osann K; Disaia PJ
Gynecol Oncol; 2005 Jan; 96(1):204-9. PubMed ID: 15589602
[TBL] [Abstract][Full Text] [Related]
37. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
Diefenbach CS; Soslow RA; Iasonos A; Linkov I; Hedvat C; Bonham L; Singer J; Barakat RR; Aghajanian C; Dupont J
Cancer; 2006 Oct; 107(7):1511-9. PubMed ID: 16944535
[TBL] [Abstract][Full Text] [Related]
38. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
39. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.
Verbruggen MB; van Diest PJ; Baak JP; Broeckaert MA; Kenemans P; Verheijen RH
Int J Gynecol Pathol; 2009 Jan; 28(1):35-40. PubMed ID: 19047910
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of frozen section diagnosis of ovarian borderline tumor.
Shih KK; Garg K; Soslow RA; Chi DS; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2011 Dec; 123(3):517-21. PubMed ID: 21920591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
